| Jeremy Cheng-yuh Wang, MD | |
|
18333 Egret Bay Blvd, Suite 200, Houston, TX 77058-3860 | |
| (281) 333-1300 | |
| (281) 333-1303 |
| Full Name | Jeremy Cheng-yuh Wang |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 26 Years |
| Location | 18333 Egret Bay Blvd, Houston, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114965928 | NPI | - | NPPES |
| 8S5380 | Other | TX | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | M2187 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Encompass Home Health Of Houston | Houston, TX | Home health agency |
| Houston Physicians' Hospital | Webster, TX | Hospital |
| Houston Methodist St John Hospital | Nassau bay, TX | Hospital |
| Hca Houston Healthcare Clear Lake | Webster, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Houston Spine And Neurosurgery Center Pa | 2466443908 | 3 |
News Archive
This German study demonstrates that the supragenual anterior cingulate cortex (ACC) is constantly activated more strongly in alexithymic subjects and that this activation is related to the symptoms of alexithymia and not to associated symptoms such as depression. These findings also support the hypothesis of an altered function of the ACC in alexithymia.
Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).
"Government representatives and leaders associated with international non-profit organizations, business and medical research convened in Los Angeles Tuesday and Wednesday at the second African First Ladies Health Summit to expand on their efforts to improve the life prospects of women and children on the continent," the Los Angeles Wave reports.
pHase Pharmaceuticals, LLC announces the launch of its new drug development company. pHase Pharmaceuticals is led by a cohesive team of drug development experts who have extensive experience bringing new drugs to market and garnering FDA approval.
Porous polymer scaffolds fabricated to support the growth of biological tissue for implantation may hold the potential to greatly accelerate the development of cancer therapeutics.
› Verified 6 days ago
| Entity Name | Houston Spine & Neurosurgery Center Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902853542 PECOS PAC ID: 2466443908 Enrollment ID: O20040521001157 |
News Archive
This German study demonstrates that the supragenual anterior cingulate cortex (ACC) is constantly activated more strongly in alexithymic subjects and that this activation is related to the symptoms of alexithymia and not to associated symptoms such as depression. These findings also support the hypothesis of an altered function of the ACC in alexithymia.
Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).
"Government representatives and leaders associated with international non-profit organizations, business and medical research convened in Los Angeles Tuesday and Wednesday at the second African First Ladies Health Summit to expand on their efforts to improve the life prospects of women and children on the continent," the Los Angeles Wave reports.
pHase Pharmaceuticals, LLC announces the launch of its new drug development company. pHase Pharmaceuticals is led by a cohesive team of drug development experts who have extensive experience bringing new drugs to market and garnering FDA approval.
Porous polymer scaffolds fabricated to support the growth of biological tissue for implantation may hold the potential to greatly accelerate the development of cancer therapeutics.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeremy Cheng-yuh Wang, MD 18333 Egret Bay Blvd, Suite 200, Houston, TX 77058-3860 Ph: (281) 333-1300 | Jeremy Cheng-yuh Wang, MD 18333 Egret Bay Blvd, Suite 200, Houston, TX 77058-3860 Ph: (281) 333-1300 |
News Archive
This German study demonstrates that the supragenual anterior cingulate cortex (ACC) is constantly activated more strongly in alexithymic subjects and that this activation is related to the symptoms of alexithymia and not to associated symptoms such as depression. These findings also support the hypothesis of an altered function of the ACC in alexithymia.
Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).
"Government representatives and leaders associated with international non-profit organizations, business and medical research convened in Los Angeles Tuesday and Wednesday at the second African First Ladies Health Summit to expand on their efforts to improve the life prospects of women and children on the continent," the Los Angeles Wave reports.
pHase Pharmaceuticals, LLC announces the launch of its new drug development company. pHase Pharmaceuticals is led by a cohesive team of drug development experts who have extensive experience bringing new drugs to market and garnering FDA approval.
Porous polymer scaffolds fabricated to support the growth of biological tissue for implantation may hold the potential to greatly accelerate the development of cancer therapeutics.
› Verified 6 days ago
Dr. Edward A M Duckworth, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1709 Dryden Rd, Suite 750 - Department Of Neurosurgery, Houston, TX 77030 Phone: 713-798-4946 Fax: 713-798-3739 | |
Joel Zachary Passer, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1515 Holcombe Blvd, Houston, TX 77030 Phone: 713-792-6161 | |
Dr. Claudio Esteves Tatsui, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1515 Holcombe Blvd, Department Of Neurosurgery -unit 442, Houston, TX 77030 Phone: 713-792-6161 | |
Dr. Omar Tanweer, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 7200 Cambridge St Fl 10, Houston, TX 77030 Phone: 713-798-1750 Fax: 713-798-4693 | |
Aaron Mohanty, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 6410 Fannin St, 1020, Houston, TX 77030 Phone: 832-325-7090 | |
Dr. Saad Ayed A Alqahatani, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 13300 Hargrave Rd Ste 500, Houston, TX 77070 Phone: 281-737-8870 | |
Dong H Kim, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 6400 Fannin St, Ste 2800, Houston, TX 77030 Phone: 713-486-8000 Fax: 713-486-8088 |